Journal updates

Spotlight on Lp(a) atherogenic mechanisms

May 10, 2024

Lp(a)-associated diacylglycerols (DAGs) and lysophosphatidic acid (LPA) have a potential role in Lp(a)-induced monocyte inflammation, according to new research investigating the atherogenicity of Lp(a).

Elevated Lp(a) linked to MACE irrespective of ASCVD history

March 20, 2024

Elevated Lp(a) is independently associated with long-term major adverse cardiovascular events (MACE), irrespective of whether patients have a history of atherosclerotic cardiovascular disease (ASCVD).

Canadian guidelines drive Lp(a) testing

March 19, 2024

A Canadian Cardiovascular Society recommendation for measuring Lp(a) at least once in a patient’s lifetime published in 2021 has had a considerable early impact on testing in the western province of Alberta. During two years after publication, 33,249 patients had a total of 37,456 Lp(a) tests.

Raised Lp(a) predicts failure to achieve LDL-C target

March 18, 2024

Elevated Lp(a) levels influence LDL-C levels and hinder the achievement of targets in patients at very high cardiovascular risk, conclude researchers who carried out a cross-sectional study in a cardiology department in Spain.

Lp(a) more atherogenic than LDL-C

March 17, 2024

Lp(a) may be as much as six times more atherogenic than LDL-C, according to results of genome-wide association studies (GWAS) using UK biobank data from over 500,000 people. Researchers identified two clusters of single nucleotide polymorphisms (SNPs): one comprising 107 variants linked to Lp(a) mass concentration, the other with 143 variants linked to LDL concentration.

EAS answers questions on Lp(a) consensus statement

June 29, 2023

In a follow up to its 2022 consensus statement on lipoprotein(a) [Lp(a)],1 the European Atherosclerosis Society (EAS) has published the answers to 30 of the most frequently asked questions about how the recommendations affect everyday clinical practice and management of atherosclerotic cardiovascular disease (ASCVD).2  They include: